FFAR2 and type 2 diabetes mellitus: Results are described in recent patent applications indicating that FFA2 agonists indeed promote GLP-1 release and that they furthermore increase glucose uptake in adipocytes, thus providing support for the notion that FFA2 agonists could be of interest for the treatment of type 2 diabetes.